Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are collectively called "Philadelphia-negative classical myeloproliferative neoplasms" (MPNs), and the discovery of the JAK2V617F mutation in 2004 led us to make new progress in the diagnostic approach and therapeutic strategy for MPNs. Thereafter, other clonal markers, such as mutations of the MPL or CALR genes, were discovered and listed as useful markers for the distinction of MPN from reactive myeloproliferation. exclusive manner in PV, ET, and PMF. In addition, a mutation of the CSF3R gene that encodes the receptor for colony stimulating factor 3, a cytokine that controls the production and differentiation of granulocytes, was shown to be an important clonal marker of chronic neutrophilic leukemia (CNL), a very rare disease entity among MPNs, based on its high frequency (∼90%) in CNLs. CSF3R mutations are also gain-of-function mutations, either missense mutations that affect the membrane-proximal extracellular domain of the protein or mutations that lead to the truncation of the protein's cytoplasmic tail. In addition to the diagnostic implications for CNL, CSF3R mutation suggests the possibility of a therapeutic response of the mutation-bearing leukemic cells to tyrosine kinase inhibitors. Direct sequencing analysis can detect both forms of CSF3R mutation. Table 1 summarizes the updated knowledge of major driver mutations in MPNs.
It is inevitable that the diagnostic criteria that we are using, currently, the 2008 WHO criteria, for the diagnosis of MPNs, will be refined. However, controversies and debate regarding diagnostic criteria still persist; for example, the reliability of the Hb level as a surrogate marker for increased red cell mass has been challenged in the diagnosis of PV. To resolve these challenging issues, proposals for the revision of the WHO diagnostic criteria were recently published [2] . The most remarkable changes are proposed in the diagnostic criteria for PV (Table 2) . First, the cut-off value for the Hb level was lowered and Hct level was listed as a new criterion. Based on a study that distinguished JAK2-mutated ET from masked PV [5] , an Hb level of 16.5 g/dL for men and 16 g/dL for women, or an Hct level of 49% in men and 48% in women, were determined to be the optimal cut-offs. Second, bone marrow morphology was promoted to a major criterion from a minor criterion, validating bone marrow morphology in PV diagnosis. Third, the endogenous erythroid colony formation test was deleted from the list of minor criteria because it is time-consuming and not generally available [6] . Finally, for a rare case of JAK2-nonmutated PV, a subnormal erythropoietin level was included as a minor criterion. For ET, the revised criteria include CALR or MPL, as well as JAK2 mutation, and one minor criterion (presence of a clonal marker, e.g. abnormal karyotype, or absence of evidence for reactive thrombocytosis) was added for cases in which there are no JAK2/ CALR/MPL mutations ( Table 2) . For PMF, a revised criterion also includes CALR or MPL, as well as JAK2 mutation. In the absence of JAK2/CALR/MPL mutations, the first minor criterion (presence of a clonal marker, e.g. abnormal karyotype, or absence of evidence for reactive BM fibrosis) aims to exclude the possibility of non-clonal bone marrow fibrosis. The second criterion (presence of anemia or palpable splenomegaly) and the third criterion (presence of leukoerythroblastosis or increased LDH level), which includes the lactose dehydrogenase level, reinforce the morphologic expression of PMF [2] (Table 2) .
We hope that the revised WHO criteria will enable us to identify patients with MPNs early and efficiently.
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